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1. Executive Summary 
Topical ophthalmic solution, commonly known as eye drops, have long been the most 
widely-used method for ocular drug delivery.  The drug delivery method, however, is 
characterized pulse delivery to the eye, which results in three consecutive stages: an initial period 
of overdose, a fairly short period of therapeutic concentration, and an extended period of sub-
therapeutic concentration.  This problem is further exacerbated by reflex tearing and blinking, 
which further dilutes and disperses the drop, causing merely 1%-7% of the drug delivered to be 
absorbed
1,2.  In recent years, researchers have proposed several designs of drug-eluting contact 
lenses to address this issue.  However, failure to achieve sustained drug release through zero-
order release kinetics remains a prevailing problem.  An imperative design requirement in an 
effective drug-eluting contact lens is for the initial burst of release that is characteristic of all 
mass transfer be followed by a sustained period of nearly constant flux. This allows the drug to 
remain within a therapeutic concentration range in the eye for a prolonged period of time.  
Further, the lens must be biocompatible and safe for use.  In this study, a contact lens was 
modeled based on the work of Ciolino et al. to release ciprofloxacin, a common antibiotic for 
treatment of infections caused by a variety of gram positive and gram negative bacterium, with 
zero-order release kinetics over many days.  COMSOL Multiphysics software was employed to 
design and stimulate the model within the parameters of commercially available contact lenses.  
To control for zero-order release, a dual polymer system was used, with an inner polymer film 
containing ciprofloxacin coated by a transparent polymer commonly used in contact lenses.  The 
former polymer modeled represents poly(lactic-co-glycolic)acid (PLGA), which is 
biocompatible and has demonstrated ability to control zero-order release kinetics
3.  This is 
possible since PLGA degrades with time, maintaining a relatively constant driving force of 
diffusion despite a finite source of drug.  The latter polymer modeled represents pHEMA, which 
is not biodegradable.  By assuming that the radius of the eye is much larger than the contact lens 
thickness, a two-dimensional, axisymmetric simulation of the system was created with the eye 
containing the following layers: tear film, epithelium, stroma, and aqueous humor (Figure 1).  
The model was run with a starting PLGA molecular mass of both 118 kDa and 18 kDa, with 
initial ciprofloxacin mass of 20mg (1:1 ratio with 118kDa PLGA).  Thus, the effect of altering 
the ratio of drug to PLGA was monitored.  The results determined that both 118kDa and 18kDa 
PLGA show sustained release of ciprofloxacin for one month after a quick initial burst, with the 
18kDa PLGA system exhibiting a higher steady state flux.  The geometry also proved to be 
superior, with the design showing a 100% increase in ciprofloxacin concentration in the eye after 
50 days over a design with PLGA spanning the width of entire lens.  This study thus exhibits 
prolonged zero-order release kinetics at a therapeutically relevant concentration can be achieved 
with a contact lens.  This prototype can be extended to further applications of ocular drug 
delivery and have enormous implications in the treatment of eye infections. 
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2. Introduction 
 
2.1. Background 
 
Topical ophthalmic solutions (eye drops) currently account for nearly all cases of ocular 
drug delivery for treatment of eye infections and glaucoma.
1The drops are administered by pulse 
delivery, resulting in a large burst of drug when the drops are administered.  However, each drop 
is quickly diluted and washed away by reflex tearing.  The small surface area of the cornea and 
the short contact time with the drops causes only 1% to 7% of the drug to be absorbed by the 
eye.
1  Consequently, large amounts of ocular drugs must be delivered to be effective.  Since the 
drug is quickly washed away, the concentration of drug in the eye decreases significantly with 
time.  Therefore, drops must be administered repeatedly, leading to widely oscillating drug 
concentrations in the eye.  Ideal treatments require constant therapeutic drug levels.  Elderly 
patients may also have difficulty using the drops properly and always remembering to administer 
them. 
Designing a sustained release system for ophthalmic drugs can avert this problem.  Drug 
delivery through a hydrogel was introduced as early as the 1960s, with most clinicians indicating 
that they would prefer to use contact lenses over eye drops.  While researchers have successfully 
designed contact lenses for delivery that are both comfortable and biocompatible, it has been 
difficult to engineer a system that demonstrates constant drug release, zero-order kinetics.  Since 
sustained release is driven by diffusion, which is dependent on the concentration gradient of the 
drug, most sustained release systems deliver drug in a large burst during the first few hours 
followed by low, subtherapeutic levels of drug elution. 
 
2.2. Research Review 
 
Ciolino et al. performed a study aimed at designing a contact lens that allows for steady 
and controlled release of drug into the eye.   A dual-polymer contact lens was used to obtain the 
desired zero order release kinetics.  The inner layer contained a biodegradable PLGA compound, 
of either 18 kDa or118 kDa, containing the molecule of interest, either fluorescein or the drug 
ciprofloxacin.  This PLGA-ciprofloxacin layer was then coated with pHEMA, a clear, non-
biodegradable compound that is used in contact lenses. 
To test the contact lens’ ciprofloxacin release kinetics, the contact lens was placed in a 
phosphate-buffered saline (PBS) solution.  The PBS solution has the same pH, salinity, and 
temperature as the human tear film to mimic drug release into the eye.  At predefined intervals, 
the PBS solution was removed, tested using high pressure liquid chromatography to determine 
the mass of ciprofloxacin present and returned.  Tests were conducted for a total of 4 weeks, 
since this is the maximum amount of time for which contact lenses are approved. 
It was found that without the aid of the contact lens, free fluorescein powder in PBS 
resulted in rapid dissolution of all of the fluorescein.  When a simple PLGA layer containing 
fluorescein was used without a surrounding pHEMA layer, the fluorescein was released quickly 
and zero-order kinetics were not obtained.  However, when a pHEMA layer coated the PLGA-
fluorescein layer, the contact lens demonstrated sustained zero-order release kinetics for 4 weeks 
for both fluorescein and ciprofloxacin.  And the release continued even at 100 days.  Other 
parameters were found to influence the release kinetics, such as the ratio of PLGA to 
ciprofloxacin or fluorescein or the mass of PLGA used.  The low molecular weight PLGA 5 
 
(18kDa) yielded faster ciprofloxacin release than the high molecular weight PLGA (118kDa).  It 
was found that the contact lens using 118 kDa PLGA released 134 µg of ciprofloxacin per day.  
If the eye produced 3 µL of tears per minute, which is greater than the average tearing rate, then 
the lens would produce a ciprofloxacin concentration of 31 µg/µL in the tears, which is 
significantly above the therapeutic level of 2 µg/µL.
1 
Therefore, Ciolino et al. effectively designed a contact lens that allowed for the zero-
order release kinetics of ciprofloxacin over the course of 4 weeks.  The amount released could be 
fine-tuned by changing the ratio of PLGA to ciprofloxacin or by changing the molecular weight 
of the PLGA used.  This design, which is effective at drug delivery to the eye, could be used for 
a wide range of applications and drugs. 
In order for the release of ciprofloxacin from the contact lens to follow zero order 
kinetics, degradation of the PLGA has to be considered.  Since the drug is constantly diffusing 
out, the gradient is thus steadily being depleted.  So for the driving force to remain the same and 
maintain constant release, the drug must be able to diffuse through the PLGA more easily as time 
progresses (i.e. the diffusivity must increase). 
The study performed by Ciolino et al. was simply experimental and, in modeling the 
delivery of ciprofloxacin to the eye, degradation of the PLGA layer must be considered.  Since 
PLGA is biodegradable, its molecular weight and diffusivity vary with time
2.  Faisant et al. 
modeled the molecular weight and diffusivity and derived Eqns. 1 and 2, as seen in Appendix A. 
 
 
2.3. Goals and Design Objectives 
 
We wish to employ COMSOL Multiphysics to determine and model the conditions at 
which this zero-order kinetics occurs. One of the lenses was designed with PLGA with molecular 
mass of 118 kDa and another with molecular mass of 18 kda.
1Furthermore, we will determine 
the concentration profile of ciprofloxacin during the time of treatment.  The minimum inhibitory 
concentration (MIC90) of ciprofloxacin to kill 90% of the bacteria is 2 µg/mL. 
We intend to use COMSOL to model ciprofloxacin release from a PLGA-coated contact 
lens, and to determine the effects of the initial ciprofloxacin concentration on the release kinetics.  
Additionally, our model eye includes the different layers (i.e. epithelium, stroma, and aqueous 
humor) which vary in diffusivity. We are taking into account that some of the drug is washed 
away due to tearing by including a degradation term in our governing equation. From the release 
profile of ciprofloxacin, we plan to model drug concentration at different points on the surface of 
the eye to determine if the drug concentration on the eye is at a therapeutic level (above MIC90). 
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2.4. Problem Schematic:  
A schematic of the proposed design is shown below.  
 
 
Figure 1: Problem schematic for contact lens made of PLGA with ciprofloxacin, coated with 
pHEMA.  A) Side view of contact lens on eye.  B) Top view of contact lens.  C) Side view of 
contact lens.  D) Schematic of contact lens with eye layers, including dimensions, as modeled in 
COMSOL.  Boundary conditions are displayed in red.  Points A and B are the boundary between 
the contact lens and the eye. 
 
3. Results and Discussion 
 
3.1. Qualitative Description of Process 
Following the procedure in Ciolino et al., the initial mass of ciprofloxacin in the PLGA 
polymer layer was set as 20mg.  Since the dimensions of the system were known (Figure 1), and 
the molecular mass of ciprofloxacin is 331.4 Da, the initial concentration of the ciprofloxacin in 
the PLGA was determined to be 4.066 * 10
3 mol/m
3.  The diffusion path of the drug was 
monitored in COMSOL over a 50-day period.  This was done for cases where the PLGA had a 
molecular mass of either 18 kDa or 118 kDa and when the PLGA was assumed either to degrade, 
altering diffusivity as seen in Figure 10, or not degrade, retaining the initial 
diffusivity values calculated above (section 2.2).  All input parameter values are listed in Table 1 
in Appendix A, below.  Three specific parameters of interest were calculated over time: average 7 
 
concentration of ciprofloxacin in the contact lens, cumulative mass of ciprofloxacin released 
from the contact lens, and the mass flux of ciprofloxacin out of the lens and into the eye. 
The average concentration of ciprofloxacin in the contact lens, that is, in both the PLGA 
and pHEMA layers, was calculated at each time point in two steps.  The integral of ciprofloxacin 
concentration values over the entire volume was calculated for both PLGA and pHEMA and 
summed. This value was then divided by the sum of the volume integral in both lens layers, 
giving the average concentration in the entire lens (Figure 2).  When degradation was 
considered, the results showed an initial burst of steep concentration change that leveled out to a 
linear decrease in concentration with time. 
 
 
Figure 2: Average ciprofloxacin concentration in the contact lens (pHEMA and PLGA) over 
time.  Orange represents a lens with an initial PLGA molecular weight of 18 kDa and constant 
diffusivity/no degradation, red represents a lens with an initial PLGA molecular weight of 118 
kDa and a constant diffusivity/no degradation, green represents a lens with an initial PLGA 
molecular weight of 18 kDa and a diffusivity varying according to Figure 10, and blue represents 
a lens with an initial PLGA molecular weight and a diffusivity varying according to Figure 10. 
Mass flux of ciprofloxacin out of the contact lens was also determined using boundary 
integration.  A surface integral of ciprofloxacin flux was computed across the interface between 
the contact lens (pHEMA surface) and the eye (tear film).  Since drug diffused into the eye, the 
flux was negative.  The absolute value of the flux was multiplied by the molecular weight of 
ciprofloxacin to yield the mass flux of ciprofloxacin entering the eye (Figure 3).  For PLGA with 
an initial molecular weight of 118 kDa, the flux has a quick initial bursts and then settled to a 
sustained, nearly constant value since the decreasing concentration gradient driving flux is 
counteracted by the increasing diffusivity shown in Figure 10.  That is, mass flux it is roughly 
linear with a slope of approximately zero, indicating a constant release rate.  However, the 8 
 
diffusivity increases significantly more for the lens with an initial PLGA molecular weight of 18 
kDa than for 118 kDa (Figure 10), which overcompensates for the decreasing concentration 
gradient.  This leads to an increase in mass flux with time after approximately 25 days for the 
lens with an intial PLGA molecular weight of 18 kDa. 
 
 
Figure 3: Flux of ciprofloxacin out of the contact lens and into the eye over time (across surface 
AB shown in Figure 1). Orange represents a lens with an initial PLGA molecular weight of 18 
kDa and constant diffusivity/no degradation, red represents a lens with an initial PLGA molecular 
weight of 118 kDa and a constant diffusivity/no degradation, green represents a lens with an 
initial PLGA molecular weight of 18 kDa and a diffusivity varying according to Figure 10, and 
blue represents a lens with an initial PLGA molecular weight of 118 kDa and a diffusivity 
varying according to Figure 10. 
Lastly, the average concentration shown in Figure 2 was multiplied by the volume of the 
lens to convert to mass remaining in the lens system.  At each time step, this value was 
subtracted from the initial mass of ciprofloxacin in the PLGA (20mg) to give the cumulative 
mass released from the contact lens (Figure 4, below).  As expected, the initial burst seen in early 
time steps leveled out to approximately a linear increase of mass release with time, which varied 
depending upon the initial diffusivity value of PLGA used.   
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3.2. Accuracy Check 
 
To assess the accuracy of our model, we compared the cumulative mass of ciprofloxacin 
released over the first 28 days from the contact lens with 118kDa PLGA to results obtained by 
Ciolino et al. (Figure 4).
1 
We obtained the cumulative mass of drug released from the contact lens by first 
calculating the average concentration of drug remaining in the contact lens (Figure 2), then 
multiplying this value by the lens volume and subtracting it from the initial mass of ciprofloxacin 
in the contact lens, 20mg.  Using the values mentioned above, specifically  m
2/s 
the mass released in the model was nearly two-fold higher than the experimental results (Figure 
4).  Therefore, one or more of the parameters must have contributed to the inaccuracy of the 
model.
 
The amount of ciprofloxacin released from the contact lens depends on the diffusivity 
within the lens, but this value was not given by Ciolino et al.  Faisant et al. found that for non-
sterilized PGLA particles, D0 is approximately  m
2/s instead of  m
2/s for 
sterilized PLGA, so the cumulative amount of drug released was recalculated using this lower D0 
value.  This yielded results significantly closer to those seen by Ciolino et al.   
 
 
Figure 4: Cumulative ciprofloxacin release from pHEMA-coated PLGA contact lens over 30 
days, with degrading PLGA with an initial molecular weight of 118 kDa, as calculated by our 
model and found experimentally by Ciolino et al.  The contact lens initially contained a total mass 
of 20 mg of ciprofloxacin.  Data from Ciolino et al. are mean ± standard deviation.  (Adapted 
from Figure 6 of Ciolino et al.)  
     Ciolino et al.  
experimental results 10 
 
3.3. Sensitivity Analysis 
 
To perform a sensitivity analysis, we varied our diffusivities, molecular mass, and 
degradation rates input variables by adding and subtracting 20% from each value (Table 3). By 
varying the values in COMSOL, we obtain the graph below, which shows the results from our 
sensitivity analysis on all 11 variables (Figure 5). 
 
Figure 5: Sensitivity analysis was performed on the 11 variables in Table 3.  Values +/- 20% 
from the original values were used in COMSOL and the resulting average ciprofloxacin in the 
contact lens after 28 days was measured. 
The initial mass of ciprofloxacin had the greatest influence on the average concentration 
of ciprofloxacin in the contact lens at 28 days.  Clearly, when the initial mass was increased, the 
average concentration of ciprofloxacin in the contact lens at 28 days was greater than the original 
value.  In addition, increasing the diffusivity of ciprofloxacin resulted in a significant drop in 
ciprofloxacin concentration in the lens.  Similarly, when the initial diffusivity was decreased, 
there was a significant increase in the amount of ciprofloxacin remaining in the contact lens after 
28 days.  The degradation constant of PLGA (kdegr), the constant k, and the diffusivity in the tear 
layer minimally influenced the concentration of ciprofloxacin in the contact lens.  The 
diffusivities of the pHEMA layer, epithelium, stroma, and aqueous humor did not cause the 
concentration of ciprofloxacin in the contact lens to change significantly, nor did the degradation 
constant in the tear layer and aqueous humor change the ciprofloxacin concentration.  Thus, it is 
more important to have extremely accurate data for the initial mass of ciprofloxacin and the 
initial diffusivity in PLGA than for the other variables. 
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4. Conclusion and Design Recommendations 
 
4.1. Interpretation of Results 
 
The underlying goal of this modeling process was to model a PLGA-coated contact 
lens and determine the conditions at which ciprofloxacin is delivered to the eye with zero 
order kinetics, allowing for sustained release.  Another goal of our contact lens model was 
for it to allow for a concentration of ciprofloxacin in the eye layers to be above the 
therapeutic threshold. 
When a constant diffusivity was used for the PLGA layer, zero-order drug release is 
not exhibited from either lens. The average concentration of ciprofloxacin in the lens did not 
decrease linearly with time (Figure 2) and the mass flux out of the lens decreased 
progressively as time increased (Figure 3), indicating non-constant release kinetics. As a 
result, it was reasoned that the diffusivity in the PLGA layer could not be modeled as a 
constant.  In fact, PLGA degrades over time, resulting in a varying diffusivity as described by 
Faisant et al.
2 
Once PLGA degradationis considered, drug release from the lens follows zero order 
kinetics. Since the drug is constantly diffusing out, the gradient is thus steadily being depleted.  
For the driving force to remain the same and maintain constant release, the drug must be able to 
diffuse through the PLGA more easily as the gradient dissipates (i.e. the diffusivity must 
increase).  In Figure 10, the diffusivity function implemented in COMSOL for the PLGA layer 
was plotted versus time for both the 18 kDa and 118 kDa molecular weight of PLGA, indicating 
that the diffusivity in the PLGA increases over time. 
  As seen in Figure 2, when PLGA degradation is included, the average concentration of 
ciprofloxacin in the contact lens (pHEMA and PLGA) decreases according to zero-order kinetics 
for both molecular weights of PLGA.  There is an initial burst of drug released followed by 
steady release for prolonged periods of time, extending past 4 weeks.  The initial burst is 
expected since initially there is a drastic concentration difference between the eye and the lens 
(i.e. the lens contains all of the drug while the eye has a concentration of zero).  Following the 
initial burst, the average concentration decreases linearly since the decreasing concentration 
gradient is counteracted by the increasing diffusivity in the PLGA layer.   
The mass flux of ciprofloxacin out of the contact lens and into the eye was also used to 
evaluate if our model obeys zero order release kinetics. As is seen in Figure 3, there is an initial 
burst with high flux followed by a fairly constant flux of ciprofloxacin between the contact lens 
and the eye.  
Lastly, the cumulative ciprofloxacin release from pHEMA-coated PLGA contact lens 
over 30 days was plotted to check for zero order release kinetics.  Figure 4 again demonstrates 
that there is an initial burst followed by a roughly linear increase.  
After confirming that our model displays zero order release kinetics, the ciprofloxacin 
concentrations in the various regions of the eye were plotted to check whether concentrations 
would reach therapeutic levels.  The therapeutic concentration of 2 µg/mL, which kills 90% of 
bacteria in the eye, was reached in the tear region and the superficial layers of the cornea, which 
is where most bacteria grow.  Therefore, the contact lens would successfully treat eye infections 
according to our model.  The ciprofloxacin concentration in the aqueous humor is over three 
orders of magnitude lower than on the surface of the eye.  However, since ocular drug delivery 
does not intend to treat infections in the aqueous humor, the low levels are not problematic.  12 
 
  Implementing this 2D axisymmetric model of ciprofloxacin being released from a contact 
lens into the eye allowed for the determination of the necessary conditions needed to achieve 
zero order release kinetics and a therapeutic level of ciprofloxacin in the eye.  It was shown that, 
under the given conditions, the contact lens exhibits sustained zero order release of ciprofloxacin 
for one month and achieves a concentration of ciprofloxacin in the eye that is above the 2 µg/mL 
therapeutic threshold.  The model being used was shown to be accurate, since it agreed with the 
results obtained by Ciolino et al. Additionally, mesh convergence and sensitivity analysis were 
performed and have furthered our model’s validity.   
 
4.2. Design Recommendations 
 
Although Ciolino et al. used the lens geometry shown in Figure 1, simpler contact lens 
geometries are possible for a sustained release system.  Contact lenses with the geometry used by 
Ciolinoet al. (as shown in Figure 1 and Figure 7) and a similar but simpler geometry, where the 
PLGA layer was a complete disk extending the diameter of the lens (as shown in Figure 6 and 
Figure 8), were modeled to evaluate the importance of the donut-shaped PLGA layer geometry.  
In both lenses, the total mass of ciprofloxacin initially in the PLGA layer was held constant at 20 
mg, the PLGA had an initial molecular mass of 118 kDa, and the PLGA degraded causing 
diffusivity to increase as shown in Figure 10.  Surface plots of ciprofloxacin concentration in the 
eye after 28 days were generated for each geometry (Figure 11).  After 28 days, the Ciolino lens 
demonstrated ciprofloxacin concentrations in the tear film and epithelial layer of approximately 
2.0 µg/mL.  However, the simplified geometry only generated ciprofloxacin concentrations of 
approximately 0.725 µg/mL in the same regions, which is below the therapeutic concentration.  
This is because much of the ciprofloxacin diffused into the upper pHEMA layer and became 
concentrated there in the simplified geometry lens (data not shown).  The hole in the PLGA layer 
in the Ciolino et al. lens allows ciprofloxacin to always diffuse from any point in the lens 
downward into the eye through the pHEMA layer.  Since the Ciolino et al. geometry allowed for 
over twice as much drug transfer into the eye, we recommend designing a lens with a similar 
geometry to that in Figure 1. 
In addition to the geometry, we recommend using an initial PLGA molecular mass of 118 
kDa.  This molecular mass caused more constant ciprofloxacin flux than the 18 kDa PLGA, as 
seen in Figure 3.  As described above, the 118 kDa case generated therapeutic concentrations of 
ciprofloxacin in the tear film and epithelial layer of the eye after times as great as 28 days, which 
is the longest approved usage time for a contact lens.  The precise dosage can be easily tuned by 
varying the total mass of ciprofloxacin initially contained in the PGLA layer during lens 
production.  In addition, a slightly lower initial PLGA molecular mass could potentially be used 
to increase the rate of drug delivery as desired. 
 
4.3. Realistic Constraints 
   
  In order to realistically manufacture the contact lens, there are certain limiting constraints 
in the design process which can be recognized by considering the perspective of both the 
manufacturer and the consumer. The manufacturer is primarily concerned with economic and 
health safety constraints, as we all as with manufacturability of the product. Our design of a 
PLGA-coated contact lens that releases ciprofloxacin is both cost-efficient and manufacturable. 
The cost will not greatly exceed regular contact lenses, since PLGA and pHEMA are commonly 13 
 
produced polymers. Furthermore, our model can be used to optimize the geometry and the 
molecular weights of all the components for a particular purpose, so the optimal characteristics 
can be determined and the contact lens can easily be produced. This will allow the manufacturer 
to sell this product at a competitive price to consumers. The efficacy of the drug delivery, as seen 
by the steady-state release, and the biocompatibility (and hence health safety) of the lens will 
encourage consumers to buy the lens. Clinical trials will have to be carried out to determine other 
safety limitations of the contact lens, such as the possible consequences if the patient forgets to 
remove the contact lens for an extended period of time. Furthermore, consumers will probably 
desire the lens to be disposable and obviously the lens should not be a hazardous waste material 
when discarded. 14 
 
5. Appendix A: Mathematical statement of problem 
 
Governing Equation: 
Mass Transfer:     
Initial Conditions:  Boundary Conditions: 
 
(Listed in schematic above in red) 
Flux across all external boundaries is 
zero due to symmetry, insulation, or 
semi-infinite conditions.  
 
 
PLGA Degradation: 
 
   (Eqn. 1) 
     (Eqn. 2) 
 
Where   is the first-order degradation constant of the polymer,   is the molecular weight 
of the non-degraded polymer,    is the diffusion coefficient for the drug in the non-degraded 
polymer, and   is a constant.  Faisant et al. experimented with PLGA of   , 78.4kDa.   They 
found that    is 0.46 weeks
-1,     is 4.9 * 10
-12cm
2/s, and   is   for 
sterilized PLGA microparticles.  These constants were used with the above equations to 
extrapolate appropriate values for 18 kDa and 118 kDa PLGA: 
 
 cm
2/s 
 cm
2/s 
Figure 6: Problem schematic for contact lens where PLGA is coated with pHEMA, except 
PLGA is a complete disk extending across the entire radius of the lens instead of just from 2 mm 
to 5 mm in the regular model shown in Figure 1.  Points A and B are the boundary between the 
contact lens and the eye. 15 
 
Table 1: Input Parameters. 
Variable  Description  Value  Citation 
m  Initial mass of ciprofloxacin  20 µg  1 
Do 
Diffusion coefficient for the 
drug in the non-degraded 
polymer 
4.9E-16 m
2/s  2 
kdegr 
First order degradation 
constant of the polymer 
7.6058E-7 s
-1 
= 0.46 week
-1  2 
k  A constant  2.1E-15 m
2/s  2 
DpHEMA  Diffusivity in pHEMA  9.9E-10 m
2/s  3 
Dtear film  Diffusivity in the tear film  5E-9 m
2/s  3 
Depithelium  Diffusivity in the epithelium  6.022E-11 m
2/s  4 
Dstroma  Diffusivity in the stroma  8.72E-13 m
2/s  4 
Daqueous humor 
Diffusivity in the aqueous 
humor  5E-9 m
2/s  5 
Rtear film 
Degradation rate in the tear 
film  -1E-4*c  3 
Raqueous humor 
Degradation rate in the 
aqueous humor  -3E-3*c  3 
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6. Appendix B: Solution strategy 
 
Solver: 
The direct (UMFPACK) solver was used to solve the algebraic equations. 
Time Stepping: 
Our model was run for a total of 30 days.  The time step used was 30 minutes.  
Tolerance: 
The relative tolerance was 0.01 and the absolute tolerance was 0.0010.   
Mesh: 
We used a free mesh that placed the most elements in the PLGA, pHEMA, tear film, and 
epithelial subdomains, since those areas experience the most ciprofloxacin diffusion.  The 
maximum element size and element type were tabulated for each subdomain (Table 2).  This 
yielded a fine mesh that had fairly short computation times and ran reliably without causing the 
computer to run out of memory (Figure 7). 
Table 2: Free mesh parameters. 
Subdomain/Boundary  Maximum Element Size (m)  Element type/method 
1. Aqueous humor    Triangle (advancing front) 
2. Stroma    Triangle 
3. Epithelial layer    Triangle 
4. Tear film    Quad 
5. pHEMA    Triangle 
6. PLGA    Triangle 
pHEMA/Tear film boundary    --- 
 17 
 
 
Figure 7: Mesh for contact lens and eye, with the dimensions shown in Figure 1. A) View of 
mesh for entire problem schematic.  B) Close-up view of mesh for pHEMA, PLGA, tear film, 
epilthelial layer, and stroma subdomains. 
The mesh for the wide PLGA layer, where the PLGA was a complete disk extending the 
diameter of the contact lens as diagrammed in Figure 6, is shown below (Figure 9).  It used the 
free mesh parameters listed in Table 2. 
 
Figure 8: Mesh for contact lens and eye, with the dimensions shown in Figure 6. 
 18 
 
 
Mesh Convergence: 
For mesh convergence analysis, the element sizes listed in Table 2 were scaled 
proportionally.  The concentration of ciprofloxacin remaining in the contact lens after 50 days 
and compared for different mesh sizes.  As shown in Figure 9, the concentration does not vary 
with increasing mesh size after a mesh size of approximately 16000 elements. Thus, we 
minimized any discretization errors by using this mesh size. 
 
Figure 9: Mesh convergence analysis, showing the average concentration of ciprofloxacin 
remaining in the lens made of 118 kDa PLGA after 50 days vs. the number of mesh elements. 19 
 
7. Appendix C: Additional visuals 
 
Figure 10: Varying diffusivity in the PLGA layer of the contact lens over time for an initial 
PLGA molecular weight of 18 kDa and 118 kDa. 20 
 
  
Figure 11: (A) Surface plot of ciprofloxacin concentration in the eye at  with the 
actual PLGA geometry in the contact lens, as shown in the schematic in Figure 1.  The contact 
lens is not included in this plot.  The initial molecular mass of PLGA modeled is 118 kDa. (B) 
Surface plot of ciprofloxacin concentration in the eye at  with the PLGA spanning 
the entire width of the contact lens, as shown in the schematic in Figure 7.  The contact lens is not 
included in this plot.  The initial molecular mass of PLGA modeled is 118 kDa.
(A) 
(B) 21 
 
Table 3: Variables to be tested for sensitivity analysis, as well as the current value used and the 
range of values that will be tested. 
Variable  Minus 20%  Current value  Plus 20% 
  16 µg  20 µg  24 µg 
  3.92E-16 m
2/s  4.9E-16 m
2/s  5.88E-16 m
2/s 
kdegr  6.08464E-7 s
-1  7.6058E-7 s
-1 
= 0.46 week
-1 
9.12656E-7 s
-1 
k  1.68E-15 m
2kDa/s  2.1E-15 m
2kDa/s  2.52E-15 m
2kDa/s 
DpHEMA  7.92E-10 m
2/s  9.9E-10 m
2/s  11.88E-9 m
2/s 
Dtear film  4E-9 m
2/s  5E-9 m
2/s  6E-9m
2/s 
Depithelium  4.8176E-11 m
2/s  6.022E-11 m
2/s  7.2264E-11 m
2/s 
Dstroma  6.976E-13 m
2/s  8.72E-13 m
2/s  10.464E-12 m
2/s 
Daqueous humor  4E-9 m
2/s  5E-9 m
2/s  6E-9m
2/s 
Rtear film  -1.2E-4*c  -1E-4*c  -.8E-4*c 
Raqueous humor  -3.6E-3*c  -3E-3*c  -2.88E-3*c 
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